IEEE Transactions on Biomedical Engineering · 2012 · 122 citations · 28 references
MedicineEndocrinologyNutritionClinical NutritionDiabetologyHuman NutritionDiabetes ControlDiabetes ManagementDiabetes MellitusGlycemic ControlHypoglycemia ManagementInsulin TherapyBlood Glucose RegulationGlucose TargetsGlycemic Control TargetsGlycemic TargetsHuman InsulinInsulin ManagementMild HypoglycemiaSevere Hypoglycemia Management
Accurate glycemic control (AGC) is difficult due to excessive hypoglycemia risk. Stochastic TARgeted (STAR) glycemic control forecasts changes in insulin sensitivity to calculate a range of glycemic outcomes for an insulin intervention, creating a risk framework to improve safety and performance. An improved, simplified STAR framework was developed to reduce light hypoglycemia and clinical effort, while improving nutrition rates and performance. Blood glucose (BG) levels are targeted to 80-145 mg/dL, using insulin and nutrition control for 1-3 h interventions. Insulin changes are limited to +3U/h and nutrition to ±30% of goal rate (minimum 30%). All targets and rate change limits are clinically specified and generalizable. Clinically validated virtual trials were run on using clinical data from 371 patients (39841 h) from the Specialized Relative Insulin and Nutrition Tables (SPRINT) cohort. Cohort and per-patient results are compared to clinical SPRINT data, and virtual trials of three published protocols. Performance was measured as time within glycemic bands, and safety by patients with severe (BG < 40 mg/dL) and mild (%BG < 72 mg/dL) hypoglycemia. Pilot trial results from the first ten patients (1486 h) are included to support the in-silico findings. In both virtual and clinical trials, mild hypoglycemia was below 2% versus 4% for SPRINT. Severe hypoglycemia was reduced from 14 (SPRINT) to 6 (STAR), and 0 in the pilot trial. AGC was tighter than both SPRINT clinical data and in-silico comparison protocols, with 91% BG within the specified target (80-145 mg/dL) in virtual trials and 89.4% in pilot trials. Clinical effort (measurements) was reduced from 16.2/day to 11.8/day (13.5/day in pilot trials). This STAR framework provides safe AGC with significant reductions in hypoglycemia and clinical effort due to stochastic forecasting of patient variation-a unique risk-based approach. Initial pilot trials validate the in-silico design methods and resulting protocol, all of which can be generalized to suit any given clinical environment.
28
Intensive Insulin Therapy in Critically Ill Patients
Greet Van den Berghe, Pieter Wouters, Frank Weekers et al. · New England Journal of Medicine · 2001 · 10K citations · Full text
Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis
Frank M. Brunkhorst, Christoph Engel, Frank Bloos et al. · New England Journal of Medicine · 2008 · 2.9K citations · Full text
Early versus Late Parenteral Nutrition in Critically Ill Adults
Michaël P. Casaer, Dieter Mesotten, Greet Hermans et al. · New England Journal of Medicine · 2011 · 1.7K citations · Full text